David R. Wise, MD, PhD, discusses the potential for pasritamig combined with docetaxel to improve outcomes in patients with mCRPC. Wise is a genitourinary medical oncologist at NYU Langone Health and ...
The management of testicular cancer continues to evolve, with advances in diagnostics, risk stratification, and multimodal treatment shaping contemporary clinical practice. At the 41st Annual Congress ...
FIT-001 enrolled ccRCC patients with prior immunotherapy, KPS ≥70, and prior cabozantinib exposure, using darlifarnib 3/5/8 mg QD (7-on/7-off) plus cabozantinib 40/60 mg. Antitumor activity was ...
CMS established permanent HCPCS J9183 for Inlexzo to support standardized claims submission and potentially reduce reimbursement-driven access delays across government and commercial payers starting ...
David Morris, MD, FACS, discusses expert panel recommendations on intravesical drug-releasing systems in bladder cancer, highlighting early drug release dynamics, tolerability, and optimizing patient ...
High-powered holmium and thulium laser platforms are expanding ureteroscopic options for complex patients, including those on anticoagulation, while emerging technologies such as Break Wave ...
In this episode of the UroOnc Minute, Wesley Yip, MD, joins host Adam B. Weiner, MD, to discuss key takeaways from LITESPARK-022, exploring the role for adjuvant pembrolizumab plus belzutifan in ...
The first patients have been treated in WOLVERINE, a prospective feasibility trial of the Edison Histotripsy System for BPH. The first patients have been treated in the WOLVERINE study (NCT07214675), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results